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1368Objective:Recently, the role ofb-blockers (BBs) in reducingperioperativemortality has been challenged.The con-
flicting results might have resulted from the extent of BB metabolism by the cytochrome P-450 (CYP2D6) isoen-
zyme. The purpose of the present studywas to assess the association between the preoperative use ofBBs dependent
on metabolism of the CYP2D6 isoenzyme with operative mortality after coronary artery bypass grafting surgery.
Methods: We performed a retrospective study of 5248 patients who had undergone coronary bypass grafting
surgery from January 1, 2001 to November 30, 2009 at Duke University Medical Center. The cohorts were
defined by the preoperative use of BBs and BB type (non-CYP2D6_BBs, CYP2D6_BBs, or no BBs). Operative
mortality was analyzed using inverse probability-weighted estimators with propensity score adjustment.
Results: Of the 5248 patients, 14% received non-CYP2D6_BBs, 43%, CYP2D6_BBs, and 43%, no BBs. The
incidence of operative mortality was 0.8%, 2.1%, and 3.7% in the non-CYP2D6_BB, CYP2D6_BB, and no BB
groups, respectively. Multivariable inverse probability-weighted–adjusted analyses showed that non-
CYP2D6_BBs were associated with a lower incidence of operative mortality (odds ratio, 0.33; 95% confidence
interval, 0.13-0.83; P¼ .02) compared with no BB use and a trend toward lower operative mortality (odds ratio,
0.44; 95% confidence interval, 0.16-1.07; P ¼ .06) compared with CYP2D6_BBs. No significant decrease
occurred in the risk of operative mortality between the CYP2D6_BB and no BB groups (odds ratio,
0.85; 95% confidence interval, 0.54-1.34; P ¼ .48).
Conclusions: Among these patients, preoperative non-CYP2D6_BB use, but not CYP2D6_BB use, was
associated with a decreased risk of operative mortality. (J Thorac Cardiovasc Surg 2014;147:1368-75)Supplemental material is available online.e Division of Cardiothoracic Anesthesiology and Critical Care,a Department
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The Journal of Thoracic and Cardiovascular SurCardiovascular morbidity and mortality are common and
costly complications in patients undergoing cardiac and
noncardiac surgery.1 Surgical coronary revascularization
has been associated with a mortality rate of 2.3% and a peri-
operative myocardial infarction rate of17%.1,2 It is widely
believed that heightened sympathetic nervous system activity
in response to surgical stress plays a fundamental role in the
development of perioperative cardiac complications and that
pharmacologic attenuation of this response with b-blockers
(BBs) will lead to improved patient outcomes.3,4
The benefits of BB therapy have recently been questioned
by reports of side effects such as hypotension and
bradycardia, which have been associated with a significantly
increased incidence of perioperative death andnonfatal stroke
in patients undergoing noncardiac surgery.4 Moreover,
accounting for demographic and clinical characteristics, the
efficacy and toxicity ofBBs in the treatment of hypertension,5
coronary artery disease,6 and heart failure have varied
significantly,7 even among nonsurgical patient populations.
A number of genetic variants with a substantial influence
on the efficacy and safety of BBs have been characterized.
including inherited differences in the metabolism of BBs.
One of the most extensively studied and characterized
examples of pharmacogenetic variation is the cytochromegery c April 2014
Abbreviations and Acronyms
BB ¼ b-blocker
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation score
IPW ¼ inverse probability weighting
OR ¼ odds ratio
PM ¼ poor metabolizer
Kertai et al Perioperative Management
P
MP-4502D6 isoenzyme or CYP2D6, which is involved in
the hepatic elimination of several drugs, including
analgesics, anti-arrhythmics, antidepressants, and most of
the lipophilic BBs (eg, metoprolol, propranolol, carvedilol,
and labetalol). This is in contrast to hydrophilic BBs, such
as atenolol and sotalol, which are eliminated largely
unchanged by glomerular filtration and, thus, independent
of CYP2D6 activity. Metoprolol is the most dependent on
this enzyme, with 70% to 80% of its biotransformation
directed through this pathway.7 Clinical studies have
observed that subjects characterized as being a CYP2D6
poor metabolizer (PM) had a significantly greater risk of
bradycardia,5,8 hypotension,5,8 and other adverse effects
during metoprolol treatment.9
In addition, BBs have a broad therapeutic index, and the
effect of PM status on the therapeutic safety of BBs metab-
olized byway of CYP2D6might become clinically apparent
only in patients at an increased risk of b-blockade, such as
patients with poor left ventricular function.3,9 Although
there is a noticeable lack of studies examining the
contribution of CYP2D6 genetic variations on the efficacy
and safety of BBs in the perioperative setting is noticeable,
Badgett and colleagues10 conducted a meta-analysis of ex-
isting trials of perioperative BB use in the setting of noncar-
diac surgery and found that increasedmortalitywas confined
to trials that had used BBs that were dependent on the
CYP2D6 metabolism. This was recently re-emphasized in
a large retrospective cohort analysis of patients undergoing
major noncardiac surgery.11 They identified stronger
associations with perioperative mortality among patients
treated with metoprolol rather than with atenolol.11 To
date, however, no randomized or observational studies
have evaluated the association between preoperative use of
BBs dependent on CYP2D6metabolism and operative mor-
tality after cardiac surgery. Therefore, using a large observa-
tional cohort of patients who had undergone CABG surgery,
we sought to determinewhether the operativemortality rates
differed for patients treated with BBs dependent on the
CYP2D6 metabolism (CYP2D6_BBs), patients treated
BBs that were independent of CYP2D6 metabolism
(non-CYP2D6_BBs), and patients without BB use.The Journal of Thoracic and CarMETHODS
Study Population
For the present retrospective observational study, we evaluated 5340
patients who had undergone off-pump or on pump CABG from January
1, 2001 to November 30, 2009 at Duke University Medical Center
(Durham, NC).
Data Collection
After obtaining approval from the institutional review board, the periop-
erative variables were collected from the Duke University Medical Center
databases, including the Automated Anesthesia Recordkeeping Database
(intraoperative BB and other cardiovascular drug use), Cardiac Surgery
Quality Assurance Database, Duke Databank for Cardiovascular Diseases,
and the patients’ electronicmedical records. Two independent investigators
(M.D.K. and S.A.E.) ascertained the data quality by performing regular
crosschecks for completeness and inconsistencies between the data set
assembled and the medical records.
Clinical Risk Factor Definitions
The potential clinical determinants of all-cause mortality collected for
the present study included patient characteristics, preoperative and intrao-
perative medication use, preoperative laboratory values (serum creatinine),
the European System for Cardiac Operative Risk Evaluation score (Euro-
SCORE; definitions of the EuroSCORE are provided in Table E1),12 and
the cardiopulmonary bypass and aortic crossclamping times. The intrao-
perative use and type of BBs, inotropes, vasopressors, and vasodilators
were also recorded.
Cardiac Medication Use
For patients with acute coronary syndromes, cardiacmedication usewas
noted on arrival at the hospital. For electively treated patients, this medica-
tion information was obtained routinely during the outpatient clinic visit
before hospital admission for cardiac surgery. A history of cardiac medica-
tion use (a-receptor blockers, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, aspirin, BBs, calcium channel blockers, clo-
pidogrel, diuretics, nitrate, statins, and warfarin) was established if the
patient had taken the medicine within 24 hours before cardiac surgery. Ac-
cording to institutional practice, the patients continued to take their medi-
cation on the evening before surgery and, absent contraindications,
resumed oral medications on postoperative day 1. Aspirin was not discon-
tinued, but clopidogrel was discontinued for 7 days before surgery.
Warfarin was discontinued 4 days preoperatively and ‘‘bridged’’ with intra-
venous heparin infusion.
The treatment groups in the present study were determined by preoper-
ative BB use and the BB type. Patients with a history of preoperative use of
carvedilol (n ¼ 254), labetalol (n ¼ 25), metoprolol (n ¼ 1936), nebivolol
(n ¼ 6), or propranolol (n ¼ 25) were assigned to the CYP2D6_BB group.
Patients with a history of preoperative use of acebutolol (n ¼ 5), atenolol
(n ¼ 695), bisoprolol (n ¼ 24), nadolol (n ¼ 12), or sotalolol (n ¼ 20)
were assigned to the non-CYP2D6_BB group. Patients with no history of
preoperative BB use were assigned to the no BB group. Those who had
received both types of BBs preoperatively—with and without CYP2D6-
dependent metabolism—were excluded from the present study. Of the
initial 5340 patients evaluated, 5248 had information available on the pre-
operative BB type used, and their data were included in our analyses.
Outcome Classification
The outcome chosen for the present study was all-cause operative mor-
tality, defined as deaths occurring during the same hospitalization as sur-
gery, regardless of timing, or within 30 days of surgery, regardless of
venue, unless the cause of death was clearly unrelated to the operation,
such as trauma.3 For patients who died at Duke University Medical Center,
the hospital records and autopsy results, when available, were retrieved anddiovascular Surgery c Volume 147, Number 4 1369
TABLE 1. Baseline characteristics of study population (n ¼ 5248)
Characteristic
BBs
P
value
No BB
group
(n ¼ 2246)
CYP2D6
group
(n ¼ 2246)
Non-
CYP2D6
group
(n ¼ 756)
Demographics
Age range (y) .017
<55 495 (22.0) 464 (20.7) 125 (16.5)
55-64 648 (28.9) 669 (29.8) 242 (32.0)
65-74 683 (30.4) 730 (32.5) 258 (34.1)
75-84 392 (17.4) 344 (15.3) 118 (15.6)
 85 28 (1.2) 39 (1.7) 13 (1.7)
Race .017
White 1755 (78.1) 1707 (76.0) 595 (78.7)
Black 368 (16.4) 435 (19.4) 132 (17.5)
Hispanic 11 (0.5) 15 (0.7) 2 (0.3)
Asian 19 (0.8) 19 (0.8) 6 (0.8)
Native American 91 (4.1) 68 (3.0) 21 (2.8)
Other 2 (0.1) 2 (0.1) 0
Female gender 643 (28.6) 655 (29.2) 230 (30.4) .641
Medical history*
EuroSCORE-related
variables
COPD 358 (15.9) 338 (15.0) 74 (9.8) .0002
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Mreviewed. In addition, the National Death Index (available at: http://www.
cdc.gov/nchs/ndi.htm) was accessed to ascertain the vital status of patients
discharged alive within 30 days of surgery.
Statistical Analysis
The baseline characteristics are presented as the mean  standard
deviation for continuous variables and as percentages and frequencies for
categorical variables. Differences between groups with a specific treatment
were assessed using the t test, analysis of variance, Kruskal-Wallis test, or
chi-square test, as appropriate.
Because the treatment assignment to preoperative BB administration
was not random, a propensity score-based approach involving inverse
probability weighting (IPW) was used to control for treatment selection
(see Supplemental methods). The effects of specific variables on mortality
(eg, non-CYP2D6_BBs or CYP2D6_BBs compared with no BBs, or a
difference between the 2 groups of BBs) were subsequently studied in
multivariable logistic regression analyses with and without weights and,
thus, providing results adjusted for treatment selection.
The discriminatory power of the final multivariable model of operative
mortality was quantified by the c-index, corresponding to the area under the
receiver operating characteristics curve, ranging from 0.5 (performance at
chance) to 1.0 (optimal performance; see Supplemental Methods).
The model fit of the final multivariable model was further assessed using
the Hosmer-Lemeshow goodness-of-fit test. Odds ratios (ORs) and the
corresponding 95% confidence intervals (CIs) are reported. The
analyses were performed using Statistical Analysis Systems, version 9.2
(SAS Institute, Inc, Cary, NC); P<.05 was considered significant.PVD 324 (14.4) 415 (18.5) 122 (16.1) .001
CVA 192 (8.5) 214 (9.5) 93 (12.3) .01
Previous cardiac
surgery
24 (1.1) 22 (1.0) 6 (0.8) .802
Chronic renal
insufficiency
173 (7.7) 267 (11.9) 50 (6.6) <.0001
Critical
preoperative
state
92 (4.1) 41 (1.9) 13 (1.7) <.0001
Unstable angina
pectoris
305 (13.6) 264 (11.8) 121 (16.0) .008
Left ventricular
function
<.0001
Normal 1112 (49.5) 1066 (47.5) 441 (58.3)
Moderate
dysfunction
908 (40.4) 917 (40.8) 273 (36.1)
Severe
dysfunction
226 (10.1) 263 (11.7) 42 (5.6)
Recent MI 723 (32.2) 485 (21.6) 146 (19.3) <.0001
Pulmonary
hypertension
14 (0.6) 16 (0.7) 3 (0.4) .64
Emergency
cardiac surgery
194 (8.6) 95 (4.2) 40 (5.3) <.0001
Postinfarct septal
rupture
10 (0.4) 1 (0.04) 1 (0.1) .016
Average logistic
EuroSCORE
3.5 (1.8-7.0) 3.3 (1.8-6.8) 3.1 (1.7-6.0) .012
Diabetes mellitus 763 (34.0) 841 (37.4) 276 (36.5) .048
Preoperative
medications
Acetylsalicylic acid 1012 (45.1) 1758 (78.3) 570 (75.4) <.0001
a-Receptor blockers 113 (5.0) 132 (5.9) 50 (6.6) .21
ACE inhibitors 609 (27.1) 1200 (53.4) 360 (47.6) <.0001
(Continued)RESULTS
The clinical characteristics of the 3 treatment groups in
the study population are listed in Table 1. Of the 5248
patients, 43% had received a CYP2D6_BB, 14%, a
non-CYP2D6_BB, and 43%, no BBs preoperatively. Of
the 5248 patients, 137 died perioperatively. Of these, 74
were cardiac deaths. Death was attributed to multiorgan
failure in 27 patients, stroke in 11 patients, and respiratory
failure in 9 patients. In the remaining 16 patients, the cause
of death was bleeding, intestinal necrosis, or vascular
thrombosis.
The data listed in Table 1 revealed statistically significant
differences among the groups for many clinical characteris-
tics, including age, race, medical history, concomitant
comorbidities, previous medications, and intraoperative
characteristics. After propensity score adjustment, no
significant imbalance was observed in the patient characte-
ristics among the groups (Table E2).
Several preoperative and intraoperative variables were
found in the univariable analysis to be significantly
associated with an increased risk of operative mortality.
However, the use of aspirin, a-receptor blockers,
angiotensin-converting enzyme inhibitors, statins, and intra-
operative esmolol and metoprolol were associated with sig-
nificant reductions in mortality risk (Table 2). In addition,
patients receiving a non-CYP2D6_BB or a CYP2D6_BB
preoperatively had a lower incidence of operative mortality
than the patients who did not receive a BB preoperatively
(0.8% and 2.1% vs 3.7%, respectively; P<.0001).1370 The Journal of Thoracic and Cardiovascular Surgery c April 2014
TABLE 1. Continued
Characteristic
BBs
P
value
No BB
group
(n ¼ 2246)
CYP2D6
group
(n ¼ 2246)
Non-
CYP2D6
group
(n ¼ 756)
Angiotensin II
receptor
antagonist
188 (8.4) 209 (9.3) 69 (9.1) .527
Calcium channel
blockers
381 (17.0) 412 (18.3) 169 (22.4) .004
Clopidogrel 145 (6.5) 432 (19.2) 123 (16.3) <.0001
Diuretics 524 (23.3) 752 (33.5) 264 (34.9) <.0001
Nitrates 334 (14.9) 957 (42.6) 311 (41.1) <.0001
Statins 734 (32.7) 1461 (65.0) 432 (57.1) <.0001
Warfarin 74 (3.3) 97 (4.3) 33 (4.4) .16
Intraoperative
characteristics
Year of surgery <.0001
2001 435 (19.4) 365 (16.3) 182 (24.1)
2002 422 (18.8) 338 (15.0) 143 (18.9)
2003 303 (13.5) 267 (11.9) 108 (14.3)
2004 227 (10.1) 208 (9.3) 85 (11.2)
2005 212 (9.4) 208 (9.3) 62 (8.2)
2006 210 (9.3) 198 (8.8) 54 (7.1)
2007 187 (8.3) 182 (8.1) 52 (6.9)
2008 154 (6.9) 222 (9.9) 34 (4.5)
2009 96 (4.3) 258 (11.5) 36 (4.8)
Surgery type .37
On-pump CABG 1921 (85.5) 1944 (86.6) 640 (84.7)
Off-pump CABG 325 (14.5) 302 (13.4) 116 (15.3)
Duration of CPB
(min)
107.7  59.9 109.9  60.6 103.9  56.4 .05
Aortic crossclamp
time (min)
59.0  36.7 59.4  35.4 56.9  34.2 .25
Intraoperative
medication
Epinephrine 1054 (46.9) 1118 (49.8) 291 (38.5) <.0001
Norepinephrine 300 (13.4) 265 (11.8) 81 (10.7) .10
Vasopressin 252 (11.2) 289 (12.9) 58 (7.7) .0001
Nitroprusside 839 (37.4) 839 (37.4) 326 (43.1) .01
Nitroglycerin 1630 (72.6) 1637 (72.9) 558 (73.8) .80
Esmolol 78 (3.5) 72 (3.2) 24 (3.2) .86
Metoprolol 1497 (66.7) 1427 (63.5) 482 (63.8) .071
Data presented as mean standard deviation, median (interquartile range), or n (%).
BB, b-Blocker; EuroSCORE, European System for Cardiac Operative Risk Evalua-
tion score; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular
disease; CVA, cerebrovascular accident; MI, myocardial infarction; ACE,
angiotensin-converting enzyme; CABG, coronary artery bypass grafting; CPB, car-
diopulmonary bypass. *The definitions of these risk factors were determined from
the definitions (Table E1) used by the EuroSCORE scoring system.12
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MIn multivariable analysis, a higher logistic EuroSCORE,
intraoperative administration of epinephrine and norepi-
nephrine, and an increased duration of cardiopulmonary
bypass remained significant predictors of operative
mortality (Table 2). Preoperative aspirin and statin use
and intraoperative administration of metoprolol were
associated with decreased operative mortality. After cor-
recting for differences in the preoperative and intraoperativeThe Journal of Thoracic and Carcharacteristics, only preoperative non-CYP2D6_BB use
was significantly associated with a lower incidence of
operative mortality compared with patients who did not
take BBs (OR, 0.34; 95% CI, 0.14-0.81; P¼ .015; Table 2).
After IPW-adjusted multivariable analysis, the association
between preoperative non-CYP2D6_BB use and a lower
incidence of operative mortality compared with no BB use
remained significant (OR, 0.33; 95% CI, 0.14-0.86;
P ¼ .02; Table 2). The final IPW-adjusted multivariable
logistic regression model for all-cause operative mortality
showed good discriminative ability and good fit (c-index,
0.775; overall goodness-of-fit Hosmer-Lemeshow test,
chi-square ¼ 6.91; P ¼ .55). The degree of overoptimism
was minimal at 0.004, which resulted in an adjusted c-index
of 0.779.
In a secondary analysis, we also tested a hypothesis of
whether the type of BB use was associated with
mortality by directly comparing CYP2D6_BBs and non-
CYP2D6_BBs and found a trend toward lower all-cause
operative mortality for non-CYP2D6_BB treatment
on IPW-adjusted multivariable analysis (OR, 0.44; 95%
CI, 0.16-1.07; P ¼ .06).
DISCUSSION
To our knowledge, this is the first study to compare
the risk of operative mortality among CYP2D6_BB, non-
CYP2D6_BB, and no BB use groups in a large population
undergoing CABG surgery. The operative mortality was
lower for the patients who had received non-
CYP2D6_BBs preoperatively than for the patients who
had received no preoperative BBs. We found, however, no
difference in operative mortality between patients taking
CYP2D6_BBs and those without preoperative BB therapy.
Our finding that metabolism by way of the CYP2D6
pathway might be associated with the efficacy of BBs has
been supported by previous pharmacogenomic studies,13-15
which have demonstrated an association between CYP2D6
genotype and the pharmacokinetics of BBs, particularly
metoprolol. The effect of the CYP2D6 genotype appears to
be large. According to clinical studies, CYP2D6 PMs had
3- to 10-fold greater plasma concentrations of metoprolol
than did subjects who were extensive metabolizers with
normal CYP2D6 activity.13,16 Furthermore, the elimination
half-life of metoprolol was found to be 7.5 hours in PMs
versus 2.8 hours in extensive metabolizers.13 In a recent
prospective trial, the plasma concentrations of metoprolol
were 4.9-fold higher in the PMs than in the non-PMs,
although the dosing was similar.5 This difference in the
plasma concentrations of metoprolol was associated with
significantly and persistently increased drug effects in the
PMs, resulting in greater reductions in heart rate, diastolic
blood pressure, and mean arterial pressure than in the
non-PMs. The more pronounced heart rate-lowering effect
in PMs was also supported by a study by Wuttke anddiovascular Surgery c Volume 147, Number 4 1371
TABLE 2. Univariable and multivariable predictors of operative mortality
Variable
Univariable analysis Multivariable analysis
Multivariable analysis,
propensity adjusted
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Demographics
Race
White 1.0
Black 0.78 (0.48-1.27) .32
Hispanic <0.001 (<0.001->999.99) .99
Asian 0.83 (0.11-6.12) .86
Native American 1.24 (0.54-2.85) .62
Other <0.001 (<0.001->999.99) .99
Patient characteristics
Diabetes mellitus 0.87 (0.61-1.25) .46
Logistic EuroSCORE per 1% increase 1.07 (1.06-1.08) <.0001 1.06 (1.05-1.07) <.0001 1.05 (1.04-1.07) <.0001
Preoperative medication
Acetylsalicylic acid 0.41 (0.29-0.58) <.0001 0.60 (0.41-0.87) .008 0.57 (0.35-0.92) .021
a-Receptor blockers 0.37 (0.12-1.17) .09
ACE inhibitors 0.69 (0.48-0.98) .04
Angiotensin II receptor antagonists 0.46 (0.20-1.06) .07
BB use
No BB group 1.0 1.0 1.0
CYP2D6 group 0.56 (0.39-0.82) .002 0.86 (0.59-1.23) .40 0.85 (0.54-1.34) .48
Non-CYP2D6 group 0.21 (0.09-0.48) <.0001 0.34 (0.14-0.81) .015 0.33 (0.13-0.83) .02
Calcium channel blockers 0.85 (0.54-1.35) .49
Clopidogrel 0.98 (0.59-1.62) .94
Diuretics 0.89 (0.61-1.30) .54
Nitrates 0.87 (0.60-1.27) .47
Statins 0.46 (0.32-0.67) <.0001 0.61 (0.42-0.90) .012 0.55 (0.33-0.90) .02
Warfarin 1.34 (0.62-2.91) .46
Intraoperative characteristics
Year of surgery per year 0.99 (0.93-1.06) .72
CPB time per 10 min 1.06 (1.04-1.09) <.0001 1.05 (1.02-1.08) .0003 1.05 (1.01-1.08) .01
Epinephrine 2.53 (1.76-3.65) <.0001 1.57 (1.05-2.34) .028 1.96 (1.21-3.19) .007
Esmolol 0.65 (0.20-2.05) .46
Metoprolol 0.54 (0.38-0.76) <.0001 0.62 (0.43-0.89) .009 0.60 (0.38-0.95) .03
Norepinephrine 1.70 (1.10-2.62) .02 1.62 (1.01-2.62) .048 1.62 (0.88-2.98) .12
Vasopressin 2.14 (1.41-3.25) <.0001
Nitroprusside 0.96 (0.68-1.36) .82
Nitroglycerin 0.90 (0.62-1.31) .58
OR, Odds ratio; CI, confidence interval; EuroSCORE, European System for Cardiac Operative Risk Evaluation score; ACE, angiotensin-converting enzyme; BB, b-blocker;
CPB, cardiopulmonary bypass.
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Mcolleagues.9 They found an overrepresentation of patients
with the PM genotype among patients with metoprolol-
associated adverse effects such as bradycardia. In a
study by Kirchheiner and colleagues,17 metoprolol use in
PMs was associated with a more pronounced lowering
of exercise-induced tachycardia. Because the plasma
concentration of metoprolol is determined largely by
CYP2D6 activity, the observed reduction in exercise-
induced tachycardia was an indication of the effect of
CYP2D6 PM status.18
In a recent meta-analysis, Badgett and colleagues10
observed that the benefit of BBs in patients undergoing
noncardiac surgery was reduced for BBs with
the CYP2D6 metabolism. Increased mortality from1372 The Journal of Thoracic and Cardiovascular Surperioperative BBs was confined to trials that had used
BBs with the CYP2D6 metabolism. These findings also
indicated that patients using BBs with the CYP2D6
metabolism were more susceptible to bradycardia, likely
caused by lower functioning genetic polymorphisms. Of
importance, patients who are ultrarapid metabolizers might
be at greater risk of operative mortality, because increased
activity of the CYP2D6 isoenzyme has been associated
with insufficient CYP2D6_BB exposure19 compared with
extensive metabolizers (normal phenotype) who will have
sufficient CYP2D6_BB exposure. However, patients who
are PMs might be at high risk of operativemortality because
of excessive CYP2D6_BB exposure. Our observation of
increased intraoperative requirements for both epinephrinegery c April 2014
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Mand vasopressin in the CYP2D6_BB group compared
with the non-CYP2D6_BB group (Table 1) is consistent
with this mechanism. Given that the prevalence of ultra-
rapid metabolizers is low (2%-3% in whites), the lack of
efficacy of CYP2D6_BBs compared with no BB use
observed in our study was likely a result of the combined
effect of sufficient exposure and too much exposure to
CYP2D6_BBs.
BBs are known to differ in their pharmacokinetic and
pharmacodynamic properties. The assumption that the
potential benefits in patients with different cardiovascular
conditions relate to a class effect might be incorrect.
Differences in half life, volume of distribution, protein
binding, and route of elimination could result in differences
in the duration, side effects, and efficacy of BBs. Several
large studies have investigated the relationship between BB
therapy and perioperative ischemic outcomes. In a group of
37,151 patients who had undergone orthopedic and
abdominal surgery, Redelmeier and colleagues20 found that
the risk of myocardial infarction and mortality was lower
in patients who had received atenolol than in those who
had received metoprolol. Wallace and colleagues21 studied
a group of 6563 patients who had undergone noncardiac
surgery and found that perioperative b-blockade with
atenolol was associated with reduced short- and long-term
mortality compared with metoprolol. In a recent study,
London and colleagues11 also studied a group of 75,610
propensity-matched patients who had undergone noncardiac
surgery and found that perioperative exposure to atenololwas
associated with a significantly lower incidence of mortality
and stroke than was metoprolol. Such anti-ischemic effects
and differences in specific BB type appear to be linked to
adequate heart rate control. According to results of a
meta-analysis of randomized trials of BB in noncardiac
surgery by Beattie and colleagues,22 effective control of the
heart rate was associated with the greatest reduction in
the incidence of postoperative myocardial infarction.
Importantly, BBs other than metoprolol resulted in more
effective control of the heart rate and less variability in the
heart rate response. The reasons for inadequate heart rate
response to BBs such as metoprolol could be multifactorial;
however, pharamacokinetic properties, including the
metabolic pathway, might significantly influence the efficacy
of BBs. Nevertheless, several other genetic and nongenetic
factors are also likely to contribute to the response and
efficacy of BBs. Such genetic factors include polymorphisms
in the adrenergic signaling pathway, introducing pharmaco-
dynamic variability,10 and nongenetic factors, such as
drug–drug interactions, release or dissolution, absorption,
and intestinal first-pass extraction.23 Furthermore, the
b1-adrenergic receptor selectivity of atenolol (the typical
non-CYP2D6_BB in our cohort) is twice superior to that
of metoprolol (the typical CYP2D6_BB).10 Given the
retrospective nature of our study, we were unable to exploreThe Journal of Thoracic and Carall the genetic and nongenetic factors thatmight influence the
efficacy of BBs.
Study Limitations
As is common with retrospective study designs, our study
had several limitations. Information on some important
predictors of operative mortality was not prospectively
collected. We used electronic medical records and
physician documentation to collect additional data on the
clinical risk factors and medication use, including type of
preoperative BBs. Thus, the effect of some risk factors
and medication use might have been biased. However, their
predictive values were similar to those reported by others
and in current guidelines.1
Although the propensity score analysis adjusted for
known confounders, other unmeasured confounders could
not be accounted for and the possibility of residual
confounding by indication could not be completely ruled
out. In addition, we defined the type of preoperative BB
as treatment received at any dose within 24 hours before
surgery. Therefore, BB therapy might not have been
optimized for all patients and the observed differences in
outcomes might have been altered if a standardized
treatment regimen had been used. Finally, our analysis
was restricted to the preoperative administration of BBs
and, given the retrospective design of our study, we could
not account for the continuation and type of BB therapy
after surgery. The potential mechanisms by which
preoperatively administered BBs might have the
influenced surgical outcome after CABG in our study
are unknown; however, factors such as a more pronounced
sympathetic rebound with the shorter half-life of
preoperatively administered metoprolol,20 the extent of
BB metabolism by CYP2D6 resulting in inconsistent
sympatholysis, or variations in BB selectivity for the
b1-adrenergic receptor associated with reduced cerebral
and renal protection could all have contributed to an
increased risk of postoperative mortality.10
Within the P-450 superfamily of drug-metabolizing
enzymes, CYP2D6 accounts for the metabolism of 25%
of marketed drugs including BBs, antidepressants, opioids,
anti-arrhythmics, and antihistamines. Many of these drugs
are substrates, inhibitors, or inducers of the CYP2D6
enzyme, and concomitant administration of a substrate
with an inhibitor or an inducer can lead to unwanted
drug–drug interactions, with implications for patient safety
in the clinical setting.24 Given the retrospective nature of
our study, we could not account for the list of medications
that would potentially be associated with drug–drug
interactions with CYP2D6_BBs and operative mortality.
However, the administration of a potent CYP2D6 inhibitor
would not be expected to cause a marked CYP2D6
drug–drug interaction for those exhibiting the PM
phenotype. In contrast, CYP2D6-mediated drug–drugdiovascular Surgery c Volume 147, Number 4 1373
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ultrarapid, extensive, or intermediate metabolizer pheno-
type.19,25 Finally, we used all-cause operative mortality,
rather than cardiac mortality, as our endpoint, which
could have resulted in a spurious association between
non-CYP2D6_BB use and outcome.CONCLUSIONS
In patients undergoing CABG surgery, preoperative
non-CYP2D6_BB use was associated with lower operative
mortality after CABG surgery. However, preoperative
CYP2D6_BB use was not associated with lower short-
term mortality.
Our findings and those from former pharmacogenomic
studies represent a step forward toward personalizing
the clinical strategies to minimize perioperative cardiac
complications and lower operative mortality according to
genotype. The robust association between the CYP2D6
genotype and pharmacokinetics of CYP2D6-dependent
BBs has provided strong evidence that the CYP2D6
genotype might influence the efficacy of BBs such as
metoprolol.5,9,10 An obvious clinical implication of the
personalized perioperative BB use could be genetic testing
for CYP2D6 variant alleles, especially in patients with a
history of side effects from BB use or in patients starting
to use CYP2D6-dependent BBs. The results of such genetic
testing could lead physicians in the perioperative setting
to consider lowering the dose of CYP2D6-dependent
BBs in PMs5,9,10 or increasing the dose in ultrarapid
metabolizers19 or to consider alternative therapy using
CYP2D6-independent BBs such as atenolol or bisoprolol.10
Information on the CYP2D6 genotype could also help
individualize the titration of perioperative analgesic,
antiarrhythmic, and antiemetic drugs that depend on the
CYP2D6 metabolism, thereby preventing adverse effects.25
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SUPPLEMENTAL METHODS
Statistical Analysis
Inverse probability weighting and treatment model. We
used the inverse probability weighting (IPW) estimators to control for treat-
ment selection.E1 The IPW creates a pseudopopulation in which each predic-
tor of treatment, including demographic characteristics, medical history
characteristics, and baseline medications, becomes balanced among the 3
groups. Three steps in thismodeling include estimation of a treatmentmodel,
calculation of individual weights, and analysis of the outcome of interest for
weighted observations.
Because the response variable (treatment group) is nominal, we used the
multinomial (or generalized) logistic model to represent the treatment in
terms of the predictors of treatment:
log

PrðT ¼ ijx1;.; xKÞ
PrðT ¼ 0jx1;.; xKÞ

¼ ai þ
XK
k¼1
bikxk; i ¼ 0; 1; 2
where ai are the 3 intercept parameters and bik are 3K slope parameters.
The following variables were used as predictors: age, race, female gender,
chronic obstructive pulmonary disease, peripheral vascular disease, cere-
brovascular accident, previous cardiac surgery, chronic renal insufficiency,
critical preoperative state, unstable angina pectoris, left ventricular
function, recent myocardial infarction, pulmonary hypertension, emer-
gency cardiac surgery, postinfarct septal rupture, diabetes mellitus, preop-
erative acetylsalicylic acid use, preoperative a-receptor blocker use,
preoperative angiotensin-converting enzyme inhibitor use, preoperative
angiotensin II receptor antagonist use, preoperative calcium channel
blocker use, preoperative clopidogrel, preoperative diuretic use,
preoperative nitrate use, preoperative statin use, preoperative warfarin
use, and year of surgery.
The model parameters were estimated by the method of maximum like-
lihood using SAS Proc LOGISTIC. The estimated parameters allowed for
estimating the linear predictors hi ¼ ai þ
PK
k¼1 bikxk and the individual
probabilities pi for obtaining the response value i as follows:
p0 ¼ 1
1þP2i¼1 expðhiÞ
for referent treatment (i ¼ 0) and
pi ¼ p0expðhiÞ
for i ¼ 1 or 2. As one can see, p0þp1þp2 ¼ 1. The estimated probabili-
ties were used to estimate the individual weights w as reciprocal of the
probability to have the actually observed treatment (ie, w ¼ 1=pi), where
i (i could be 0, 1, or 2) is the treatment observed for the given patient.
Discriminatory Power
To further evaluate the discriminatory power of the final multivariable
model, the bootstrap method using 1000 bootstrap samples of the size of
the original cohort was used to assess the degree of overoptimism. Overop-
timization occurs when application of the statistical modeling techniques
results in models that inaccurately predict the outcomes on subsequent
data sets. A bootstrapping procedure is 1 method that can be used to try
to correct for this overoptimism.E2 The distribution of the c-index
statistics was evaluated and compared for the calculations with and without
the weights adjusting the results of treatment selection.
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TABLE E1. Definition of variables in the EuroSCORE risk model
Risk factor STS definition match
1. Age Per 5 y or part thereof>60 y
2. Gender Female
3. Chronic pulmonary disease Patient requires pharmacologic therapy for treatment of chronic pulmonary compromise or patient had
FEV1<75% of predicted value
4. Extracardiac arteriopathy Patient has peripheral vascular disease as indicated by claudication with either exertion or rest; amputation for
arterial insufficiency; aortoiliac occlusive disease reconstruction; peripheral vascular bypass surgery;
angioplasty or stent; documented abdominal aortic aneurysm, abdominal aortic aneurysm repair, or stent;
positive noninvasive testing documented—or—patient has cerebrovascular disease, documented by any 1 of the
following: unresponsive coma for>24 h; CVA (symptoms for>72 h after onset); RIND (recovery within 72 h);
TIA (recovery within 24 h); or noninvasive carotid test results with 75% occlusion
5. Neurologic dysfunction disease A central neurologic deficit persisting>24 h
6. Previous cardiac surgery Previous cardiac surgical operations with or without CPB
7. Serum creatinine >200 mmol/L preoperatively
9. Critical preoperative state Any1 of the following: sustained ventricular tachycardia or ventricular fibrillation requiring cardioversion and/
or intravenous amiodarone, preoperative inotropic support, preoperative intra-aortic balloon pump, or patient
required cardiopulmonary resuscitation within 1 h before the start of the operative procedure
10. Unstable angina Preoperative use of intravenous nitrates
11. Left ventricular dysfunction Normal, LVEF>50%; moderate, LVEF 30%-50%; severe, LVEF<30%
12. Recent MI <21 d
13. Pulmonary hypertension Systolic pulmonary artery pressure>30 mm Hg
14. Emergency Procedure status is emergent or salvage. Emergent: the patient’s clinical status includes any of the following: (1)
ischemic dysfunction (any of the following): (a) ongoing ischemia, including ret angina despite maximal
medical therapy (medical and/or IABP); (b) acute evoking myocardial infarction within 24 h before surgery;
and/or (c) pulmonary edema requiring intubation; (2) mechanical dysfunction (either of the following): (a)
shock with circulatory support; or (b) shock without circulatory support. Salvage: the patient is undergoing CPR
en route to the OR or before anesthesia induction
15. Other than isolated CABG Any valve procedure in addition to or separate from CABG
16. Surgery on thoracic aorta Aortic aneurysm/dissection repair
17. Postinfarct septal rupture Ventricular septal defect
EuroSCORE, European System for Cardiac Operative Risk Evaluation score; STS, Society of Thoracic Surgery; FEV1, forced expiratory volume in 1 second; RIND, reversible
ischemic neurologic deficit; TIA, transient ischemic attack; LVEF, left ventricular ejection fraction;MI,myocardial infarction; IABP, intra-aortic balloon pump; CPR, cardiopul-
monary resuscitation; OR, operating room; CABG, coronary artery bypass grafting. Data from Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R.
European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9-13.
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TABLE E2. Baseline characteristics after propensity score
adjustment (n ¼ 5248)
Characteristic
BBs
P
value
No BB
group
(n ¼ 2246)
CYP2D6
group
(n ¼ 2246)
Non-CYP2D6
group
(n ¼ 756)
Demographics
Age range (y) .37
<55 20.49 19.92 16.92
55-64 29.23 29.34 32.21
65-74 31.17 32.42 33.85
75-84 17.67 16.6 15.29
 85 1.44 1.74 1.74
Race .37
White 77.97 76.02 77.31
Black 17.65 19.61 18.3
Hispanic 0.43 0.63 0.35
Asian 0.8 1.01 0.88
Native American 3.05 2.68 3.16
Other 0.09 0.05 0
Female gender 30.21 29.51 30.08 .94
Medical history
EuroSCORE-
related
variables*
COPD 15.75 15.43 14.41 .74
PVD 16.85 16.92 17.53 .91
CVA 10.0 10.0 10.44 .93
Previous cardiac
surgery
1.03 1.07 1.17 .96
Chronic renal
insufficiency
36.56 36.77 35.94 .93
Critical
preoperative
state
2.63 2.68 2.63 .99
Unstable angina
pectoris
12.26 12.84 13.29 .77
Left ventricular
function
.27
Normal 49.46 50.98 50.47
Moderate
dysfunction
41.85 39.03 42.13
Severe
dysfunction
8.69 9.99 7.39
Recent MI 23.35 23.29 25.24 .54
Pulmonary
hypertension
0.61 0.94 0.41 .40
Emergency
cardiac
surgery
5.75 5.73 6.2 .89
Postinfarct septal
rupture
0.2 0.04 0.08 .26
Diabetes mellitus 10.65 9.7 9.55 .74
Preoperative
medications
Acetylsalicylic acid 66.26 66.58 66.79 .97
(Continued)
TABLE E2. Continued
Characteristic
BBs
P
value
No BB
group
(n ¼ 2246)
CYP2D6
group
(n ¼ 2246)
Non-CYP2D6
group
(n ¼ 756)
a-Receptor
blockers
6.11 6.17 6.15 .99
ACE inhibitors 43.68 43.2 43.69 .97
Angiotensin II
receptor
antagonist
10.06 9.54 9.45 .88
Calcium channel
blockers
20.69 20.58 20.65 .99
Clopidogrel 15.33 14.04 14.8 .75
Diuretics 32.92 31.07 33.33 .54
Nitrates 33.63 31.79 33.12 .68
Statins 52.62 52.36 52.63 .99
Warfarin 4.35 4.07 3.85 .84
Year of surgery .84
2001 18.28 18.58 17.51
2002 16.32 17.78 16.87
2003 12.96 12.81 13.43
2004 9.28 9.04 11.81
2005 9.76 9.65 9.29
2006 9.13 8.6 9.08
2007 8.95 7.2 8.4
2008 8.31 8.25 6.7
2009 7.03 8.1 6.92
Data presented as percentages. For method of propensity score adjustment,
see the ‘‘Statistical Analysis’’ section in the ‘‘Methods’’ section. BB, b-Blocker;
EuroSCORE, European System for Cardiac Operative Risk Evaluation score;
COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease;
CVA, cerebrovascular accident; MI, myocardial infarction; ACE, angiotensin-
converting enzyme. *The definitions of these risk factors were determined from the
definitions (Table E1) used by the EuroSCORE scoring system [Nashef SA, Roques
F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac
operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9-13.]
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